KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Finished Goods (2016 - 2025)

Historic Finished Goods for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $144.5 million.

  • Halozyme Therapeutics' Finished Goods rose 105.64% to $144.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $144.5 million, marking a year-over-year increase of 105.64%. This contributed to the annual value of $144.5 million for FY2025, which is 105.64% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Finished Goods is $144.5 million, which was up 105.64% from $161.6 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Finished Goods ranged from a high of $164.9 million in Q2 2025 and a low of $25.8 million during Q4 2021
  • In the last 5 years, Halozyme Therapeutics' Finished Goods had a median value of $61.1 million in 2023 and averaged $82.1 million.
  • Data for Halozyme Therapeutics' Finished Goods shows a peak YoY increase of 20098.91% (in 2021) and a maximum YoY decrease of 1638.58% (in 2021) over the last 5 years.
  • Over the past 5 years, Halozyme Therapeutics' Finished Goods (Quarter) stood at $25.8 million in 2021, then surged by 78.28% to $46.0 million in 2022, then skyrocketed by 52.12% to $69.9 million in 2023, then surged by 104.41% to $142.9 million in 2024, then grew by 1.06% to $144.5 million in 2025.
  • Its last three reported values are $144.5 million in Q4 2025, $161.6 million for Q3 2025, and $164.9 million during Q2 2025.